Benefit- risk – forholdet for Hexavac er derfor stadig positivt, og det er ikke nødvendigt at træffe yderligere forskriftsmæssige foranstaltninger på dette tidspunkt.
However, the strength of this signal is, in the absence of a convincing biological and causal link, weak, therefore the benefit-risk balance for Hexavac remains positive and no further regulatory action is necessary at this point in time.